Artificial COVID-19 T-Cell Immunogen
An artificial T-cell immunogen consisting of conserved fragments of different proteins of the SARS-CoV-2 virus and its immunogenic properties were studied in BALB/c mice. To create a T-cell immunogen, we used an approach based on the design of artificial antigens that combine many epitopes from the main proteins of the SARS-CoV-2 virus in the one molecule. The gene of the engineered immunogen protein was cloned as part of the pVAX1 plasmid in two versions: with an N-terminal ubiquitin and without it. The obtained plasmids were analyzed for their ability to provide the synthesis of the immunogen protein in vitro and in vivo. It has been shown that protein product of the created artificial genes is actively processed in HEK293T cells and induces cellular immunity in mice..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:175 |
|---|---|
| Enthalten in: |
Bulletin of experimental biology and medicine - 175(2023), 6 vom: Okt., Seite 804-809 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Borgoyakova, M. B. [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
Artificial T-cell immunogen |
|---|
| Anmerkungen: |
© Springer Science+Business Media, LLC, part of Springer Nature 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
|---|
| doi: |
10.1007/s10517-023-05951-7 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR053919556 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR053919556 | ||
| 003 | DE-627 | ||
| 005 | 20231201064639.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231201s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10517-023-05951-7 |2 doi | |
| 035 | |a (DE-627)SPR053919556 | ||
| 035 | |a (SPR)s10517-023-05951-7-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Borgoyakova, M. B. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Artificial COVID-19 T-Cell Immunogen |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © Springer Science+Business Media, LLC, part of Springer Nature 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. | ||
| 520 | |a An artificial T-cell immunogen consisting of conserved fragments of different proteins of the SARS-CoV-2 virus and its immunogenic properties were studied in BALB/c mice. To create a T-cell immunogen, we used an approach based on the design of artificial antigens that combine many epitopes from the main proteins of the SARS-CoV-2 virus in the one molecule. The gene of the engineered immunogen protein was cloned as part of the pVAX1 plasmid in two versions: with an N-terminal ubiquitin and without it. The obtained plasmids were analyzed for their ability to provide the synthesis of the immunogen protein in vitro and in vivo. It has been shown that protein product of the created artificial genes is actively processed in HEK293T cells and induces cellular immunity in mice. | ||
| 650 | 4 | |a SARS-CoV-2 |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a DNA vaccine |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a artificial T-cell immunogen |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a T-cell immune response |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a vaccine design |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Karpenko, L. I. |4 aut | |
| 700 | 1 | |a Rudometov, A. P. |4 aut | |
| 700 | 1 | |a Starostina, E. V. |4 aut | |
| 700 | 1 | |a Zadorozhny, A. M. |4 aut | |
| 700 | 1 | |a Kisakova, L. A. |4 aut | |
| 700 | 1 | |a Kisakov, D. N. |4 aut | |
| 700 | 1 | |a Sharabrin, S. V. |4 aut | |
| 700 | 1 | |a Ilyichev, A. A. |4 aut | |
| 700 | 1 | |a Bazhan, S. I. |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Bulletin of experimental biology and medicine |d Dordrecht [u.a.] : Springer Science + Business Media B. V., 1956 |g 175(2023), 6 vom: Okt., Seite 804-809 |w (DE-627)SPR010703306 |w (DE-600)2037110-X |x 1573-8221 |7 nnns |
| 773 | 1 | 8 | |g volume:175 |g year:2023 |g number:6 |g month:10 |g pages:804-809 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s10517-023-05951-7 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 951 | |a AR | ||
| 952 | |d 175 |j 2023 |e 6 |c 10 |h 804-809 | ||